Bangkok Post

Exec who jacked up drug price nabbed

Bureau slams fraud charges on Shkreli

-

NEW YORK: A boyish-looking entreprene­ur who became the new face of corporate greed when he jacked up the price of a lifesaving drug by 50 times was led away in handcuffs by the FBI on unrelated fraud charges on Thursday in a scene that left more than a few US citizens positively gleeful.

Martin Shkreli, a 32-year-old former hedge fund manager and relentless selfpromot­er who has called himself “the world’s most eligible bachelor” on Twitter, was arrested in a grey hoodie and taken into federal court in Brooklyn, where he pleaded not guilty. He was released on US$5 million (1.8 billion baht) bail.

If convicted, he could get up to 20 years in prison. He left court without speaking to reporters. His lawyers had no immediate comment.

Hours later, Mr Shkreli tweeted: “Glad to be home. Thanks for the support.”

Online, many people took delight in his arrest, calling him a greedy, arrogant “punk” who gave capitalism a bad name and got what was coming to him. Some cracked jokes about lawyers jacking up their hourly fees 5,000% to defend him in his hour of need.

Prosecutor­s said that between 2009 and 2014, Mr Shkreli lost some of his hedge fund investors’ money through bad trades, then looted Retrophin, a pharmaceut­ical company where he was CEO, for $11 million to pay back his disgruntle­d clients.

“Mr Shkreli engaged i n multiple schemes to ensnare investors through a web of lies and deceit,” US lawyer Robert Capers said.

Mr Shkreli was charged with securities fraud and conspiracy. A second defendant, lawyer Evan Greebel, of Scarsdale, New York, was charged with conspiracy and also pleaded not guilty.

A spokesman for Mr Shkreli released a statement saying he denies the charges and “expects to be fully vindicated”.

“It is no coincidenc­e that these charges, the result of investigat­ions which have been languishin­g for a considerab­le time, have been filed at the same time of Shkreli’s high-profile, controvers­ial and yet unrelated activities,” spokesman Craig Stevens said.

In September, Mr Shkreli was widely vilified after a drug company he founded, Turing Pharmaceut­icals, spent $55 million for the US rights to sell a medicine called Daraprim and promptly raised the price from $13.50 to $750 per pill.

The 62-year-old drug is the only approved treatment for toxoplasmo­sis, a rare parasitic disease that mainly strikes pregnant women, cancer and Aids patients.

The move sparked outrage on the presidenti­al campaign trail and helped prompt a Capitol Hill hearing on drug prices. Headlines called the Brooklyn-born Mr Shkreli such thing as “America’s most hated man” the “Drug industry’s villain” and “Biotech’s bad boy” — and those were just some of the more printable names.

Hillary Clinton called it price-gouging and said the company’s behaviour was “outrageous”. Donald Trump called Mr Shkreli “a spoiled brat”. Bernie Sanders returned a donation from Mr Shkreli.

Prosecutor­s said the investigat­ion that led to Mr Shkreli’s arrest dated back to last year, before the furore over the drugprice increase.

Mr Shkreli defended the increase by saying that insurance and other programmes would enable patients to get the drug.

But he also made an unapologet­ic business-is-business argument for the price jump. In fact, he recently said he probably should have raised it more.

“No one wants to say it, no one’s proud of it, but this is a capitalist society, a capitalist system and capitalist rules,” he said in an interview at the Forbes Healthcare Summit this month. “And my investors expect me to maximise profits, not to minimise them or go half or go 70% but to go to 100% of the profit curve.”

Amid the uproar, Mr Shkreli said Turing would cut the price of Daraprim.

The company is reducing what it charges hospitals for Daraprim by as much as 50%.

While most patients’ payments will be $10 or less a month, insurance companies will be stuck with the bulk of the tab, potentiall­y driving up future treatment and insurance costs.

Robert Weissman, president of the watchdog group Public Citizen, said Mr Shkreli got “a deserved comeuppanc­e”.

“Al Capone was brought down for tax evasion, but he committed many worse crimes,” Mr Weissman said.

“So if Shkreli’s arrested for securities violations, it’s a comparable justice.”

Mr Shkreli is known as a prolific user of Twitter.

He often livestream­s his work day over the internet, inviting people to chat with him at his desk. He refers to those who follow him online as his “fans”.

Recently it emerged that he bought the only copy of a Wu-Tang Clan album titled Once Upon a Time in Shaolin, which the hip-hop group sold on the condition that it not be released publicly. He said he paid $2 million.

The FBI’s New York office said agents did not seize Mr Shkreli’s album.

 ?? BLOOMBERG ?? Martin Shkreli, chief executive officer of Turing Pharmaceut­icals LLC, exits the federal court in New York on Thursday. Mr Shkreli was arrested on alleged securities fraud related to Retrophin, a biotech firm he founded in 2011.
BLOOMBERG Martin Shkreli, chief executive officer of Turing Pharmaceut­icals LLC, exits the federal court in New York on Thursday. Mr Shkreli was arrested on alleged securities fraud related to Retrophin, a biotech firm he founded in 2011.

Newspapers in English

Newspapers from Thailand